In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition
Broad tumor-agnostic ctDNA analysis effectively identified clinically relevant mutations and predicted outcomes in ICI-treated melanoma patients. This approach enables tissue-independent and real-time ctDNA monitoring and may inform patient selection and therapeutic strategies in future interventional trials.
Authors
- Daniel J. Smit (ORCID: https://orcid.org/0000-0002-3190-9511)
- Christoffer Gebhardt (ORCID: https://orcid.org/0000-0001-7090-9584)
- Stefan Bonn (ORCID: https://orcid.org/0000-0003-4366-5662)
- Julian Kött (ORCID: https://orcid.org/0000-0003-2073-3909)
- Anne Menz (ORCID: https://orcid.org/0000-0002-4364-6464)
- Isabel Heidrich (ORCID: https://orcid.org/0000-0001-6894-1913)
- Glenn Geidel (ORCID: https://orcid.org/0009-0008-3999-5902)
- Klaus Pantel (ORCID: https://orcid.org/0000-0001-5736-2772)
- Finn Abeck (ORCID: https://orcid.org/0000-0001-7823-0736)
- Alessandra Rünger (ORCID: https://orcid.org/0000-0002-4465-5282)
- Cedric Ly
- Stefan W. Schneider (ORCID: https://orcid.org/0000-0002-4679-7137)
- Charlotte Rautmann
- Robin Khatri (ORCID: https://orcid.org/0009-0006-5311-1718)
- Antje Andreas
- Inga Hansen-Abeck (ORCID: https://orcid.org/0000-0002-9188-861X)
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Cancer Center Hamburg (DE)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1186/s13046-025-03457-w
- Citations
- 7
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 6.55
Funders
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
- Universitätsklinikum Hamburg-Eppendorf